FindTrial
Sign In

Multiple-Dose, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2439821 in Japanese Patients with Rheumatoid Arthritis on Concomitant Methotrexate Treatment

Multiple-Dose, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2439821 in Japanese Patients with Rheumatoid Arthritis on Concomitant Methotrexate Treatment

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221108
Enrollment
Unknown
Registered
2010-05-21
Start date
2010-05-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

investigational material(s) Generic name etc : LY2439821 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigat

Sponsors

Eli Lilly Japan K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Eligible patients are those who have rheumatoid arthritis according to the American Rheumatism Association 1987 revised criteria, who have used methotrexate for at least 12 weeks and have been on a stable dose, at least 7.5 mg/week, for no less than 8 weeks. Serum C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) values must be more than the upper limit of normal (ULN) at study entry.

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026